Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Alcoholic Hepatitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Alcoholic Hepatitis - Pipeline Review, H2 2014', provides an overview of the Alcoholic Hepatitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Alcoholic Hepatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Alcoholic Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Alcoholic Hepatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Alcoholic Hepatitis Overview 6 Therapeutics Development 7 Pipeline Products for Alcoholic Hepatitis - Overview 7 Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 8 Alcoholic Hepatitis - Therapeutics under Development by Companies 9 Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 10 Alcoholic Hepatitis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Alcoholic Hepatitis - Products under Development by Companies 13 Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 14 Alcoholic Hepatitis - Companies Involved in Therapeutics Development 15 Immuron Limited 15 Conatus Pharmaceuticals Inc. 16 Intercept Pharmaceuticals, Inc. 17 Alfact Innovation 18 Generon (Shanghai) Corporation Ltd. 19 Alcoholic Hepatitis - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 obeticholic acid - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 emricasan - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 IMM-124E - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ALF-5755 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 F-652 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Alcoholic Hepatitis - Recent Pipeline Updates 42 Alcoholic Hepatitis - Dormant Projects 49 Alcoholic Hepatitis - Product Development Milestones 50 Featured News & Press Releases 50 Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 50 Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Number of Products under Development for Alcoholic Hepatitis, H2 2014 7 Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Alcoholic Hepatitis - Pipeline by Immuron Limited, H2 2014 15 Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 16 Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 17 Alcoholic Hepatitis - Pipeline by Alfact Innovation, H2 2014 18 Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Alcoholic Hepatitis Therapeutics - Recent Pipeline Updates, H2 2014 42 Alcoholic Hepatitis - Dormant Projects, H2 2014 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.